Menu Search
Equities

TuHURA Biosciences Inc

3DMA:DEU

TuHURA Biosciences Inc

Actions
  • Price (EUR)6.44
  • Today's Change0.00 / 0.00%
  • Shares traded28.43
  • 1 Year change-47.43%
  • Beta--
Data delayed at least 15 minutes, as of Oct 17 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

TuHURA Biosciences, Inc. is a Phase III registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The Company’s lead personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase III registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first line treatment for advanced Merkel cell carcinoma. In addition, the Company is leveraging its Delta receptor technology to develop novel bi-functional antibody drug conjugates (ADCs), targeting myeloid derived suppressor cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies. Its IFx platform technology utilizes a proprietary plasmid DNA (pDNA) or messenger RNA (mRNA).

  • Revenue in USD (TTM)0.00
  • Net income in USD-8.50m
  • Incorporated2009
  • Employees1.00
  • Location
    TuHURA Biosciences Inc10500 University Center Dr., Suite 110TAMPA 33612United StatesUSA
  • Phone+1 (813) 875-6600
  • Fax+1 (604) 202-1384
  • Websitehttps://www.kintara.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		HURA:NAQ since
announced		Transaction
value
TuHURA Biosciences IncAnnounced03 Apr 202403 Apr 2024Announced40.17%--
Data delayed at least 15 minutes, as of Nov 13 2024 19:09 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.